Monitor for definitive agreements by late March 2026 and watch for financing activities to fund the $3 million cash component, possibly through an equity line or Nasdaq uplisting.
Price Chart
Executive Summary
Totaligent, Inc. entered into a binding letter of intent to form a joint venture with GloMed Solutions and acquire it within one year via a call option. The acquisition consideration is $3 million in cash and 15% of Totaligent's fully diluted equity, based on GloMed's $10 million annual revenue and $1 million free cash flow.
Key Financial Metrics
Key Facts
- Totaligent will form a joint venture with GloMed Solutions to integrate its Aetherium Medical platform with GloMed's APAC distribution network.
- GloMed has approximately $10 million in annual revenue and $1 million in free cash flow.
- Totaligent receives a one-year call option to acquire 100% of GloMed for $3 million in cash plus 15% of Totaligent's fully diluted common stock.
- The joint venture targets a March 22, 2026 closing, with definitive agreements to be negotiated within four weeks.
- Totaligent will have strategic control of the JV with three board seats, including Edward DeFeudis, Don Heath, and Ivan Klarich.
Financial Impact
Acquisition valued at $3 million cash plus 15% of Totaligent's equity; target company generates $10 million revenue and $1 million FCF annually.
Risk Factors
- Definitive agreements may not be finalized within the target timeframe.
- The acquisition is contingent on a PCAOB-compliant audit of GloMed's Japanese operations.
- The 15% equity issuance represents significant dilution to existing shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (TGNT) — Batch item 1 | 0001477932-26-001016 |
| Document: totaligent_8k.htm | 0001477932-26-001016 |
| Document: 0001477932-26-001016-index-headers.html | 0001477932-26-001016 |
| Document: 0001477932-26-001016-index.html | 0001477932-26-001016 |
| Document: 0001477932-26-001016.txt | 0001477932-26-001016 |
| 8-K Filing (TGNT) — Batch item 6 | 0001477932-26-001016 |
| Document: totaligent_8k.htm | 0001477932-26-001016 |
| Document: 0001477932-26-001016-index-headers.html | 0001477932-26-001016 |
| Document: 0001477932-26-001016-index.html | 0001477932-26-001016 |
| Document: 0001477932-26-001016.txt | 0001477932-26-001016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 15, 2026 27w ago | 8-K | $0.0150 $0.007000 | ▼ −53.33% | ▼ −61.47% | $0.006000 (−60.00%) |
Feb 25, 2026 34w ago | 8-K | $0.0130 $0.0220 | ▲ +69.23% | ▲ +62.28% | $0.006000 (−53.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers